Bayer Tightens Its Grip on Specialty Pharma Even as €33 Billion Debt Burden Weighs

Bayer closes $300M Perfuse Therapeutics acquisition, unveils 16 ASCO presentations, but faces €33B debt and glyphosate litigation cash outflows of €5B in 2026.

The Leverkusen-based conglomerate is sprinting in two directions at once. On one hand, the completion of a targeted biotech acquisition and a strong showing at the world's largest cancer conference are burnishing its pipeline credentials. On the other, a churning legal legacy and a balance sheet groaning under nearly €33 billion in net debt threaten to cap any sustained share-price rally.

Bayer has closed the purchase of California-based Perfuse Therapeutics, a deal that centres on the ocular implant PER-001. The drug, now in Phase II trials, aims to treat glaucoma and retinal diseases. Bayer will pay $300 million upfront, with potential milestone payments lifting the total consideration to $2.45 billion. Market observers view the move as a deliberate hedge against looming patent expiries in the pharma division.

The acquisition came alongside a notable presence at the American Society of Clinical Oncology (ASCO) meeting, where Bayer unveiled 16 research presentations. Among the highlights was the Phase II ARACOG study for its prostate cancer drug Nubeqa, which directly compares the agent with Enzalutamide. The group also secured US Food and Drug Administration approval for the contrast agent Gadoquatrane, while its promising stroke candidate Asundexian remains under review by the European Medicines Agency. Asundexian has yet to win a single global marketing authorisation.

Yet for all the pipeline progress, the glyphosate storm continues to drain cash. The company expects litigation-related cash outflows of roughly €5 billion in 2026 alone, a figure that underscores the provisions already set aside. Free cash flow for the current year is forecast to be negative, ranging between minus €1.5 billion and minus €2.5 billion, while revenue growth is seen at a currency-adjusted ceiling of 3%.

On the legal front, Bayer notched a procedural win when Germany’s National Contact Point of the OECD closed a long-standing complaint against the group. Several non-governmental organisations had accused Bayer of health damages in South America linked to glyphosate and genetically modified seeds, but declined mediation, prompting the closure. Analysts see the move as a modest de-risking.

All eyes, however, remain on the US Supreme Court. A decision in the “Durnell” case, expected by the end of June, could determine whether federal law preempts state-level labelling requirements. A ruling in Bayer’s favour would slash the remaining litigation burden. For now, the stock must contend with a resistance zone near the 12-month high of roughly €50.

The shares have responded to the mixed picture with volatile gains. On one recent session, Bayer advanced 3.58% to €39.88, and on another it added 2.86% to €39.60. The equity now sits well above its 200-day moving average of €36.39, with a distance of nearly 9% from that level. The relative strength index (RSI) stands at 64.3, reflecting the recent upward momentum without tipping into overbought territory.

Away from the courtroom and the lab, the group is also seeking growth in Asia. Its Indian subsidiary has repositioned Alka Seltzer as a probiotic-infused antacid, targeting the country’s ayurvedic self-medication market. Management sees India offering substantial potential for over-the-counter products.

The path to a full re-rating, however, hinges on clinical catalysts. If Bayer can deliver compelling data from its oncology and ophthalmology pipelines in the coming months, the €50 resistance level may yet be tested. Until then, the tug-of-war between pipeline promise and financial drag will keep the stock in a narrow, high-stakes trading range.